In preclinical stroke models, pharmacological inhibition of cathepsin L reduced infarct volume and improved neurobehavioral outcomes, though it remains unclear whether cathepsin L actively contributes to infarct expansion or simply reflects secondary inflammatory processes. This evidence concerns the gene CTSL and stroke disorder.